Skip to main content
KANGSTEM BIOTECH CO., LTD. logo

KANGSTEM BIOTECH CO., LTD. — Investor Relations & Filings

Ticker · 217730 ISIN · KR7217730001 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2025-05-26 Regulatory Filings
Country KR South Korea
Listing KO 217730

About KANGSTEM BIOTECH CO., LTD.

https://kangstem.com

KANGSTEM BIOTECH CO., LTD. is a biopharmaceutical company that researches and develops advanced stem cell therapies. The company focuses on creating treatments for rare, incurable, and autoimmune diseases, with a pipeline that includes therapeutic candidates for neurological disorders. Leveraging proprietary technologies for the isolation and mass culture of mesenchymal stem cells, Kangstem Biotech also develops and commercializes stem cell culture media and related cosmetic products. The company is dedicated to addressing unmet medical needs through the development of next-generation biopharmaceuticals.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험계획승인신청) (중등도 및 중증 ARDS 환자대상 hUCB-MSC3-XT Inj.의 호주 제1상 임상시험계획 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean biotech company (Kangstem Biotech) announcing the submission of a Phase 1 clinical trial application in Australia. It follows the standard format for 'Major Management Matters' (주요경영사항) in the Korean market, which is used to disclose significant corporate events such as clinical trial progress. Since it does not fit into specific categories like financial reports, dividends, or M&A, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2025-05-26 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Kangstem Biotech, covering the period from January 1, 2025, to March 31, 2025. It contains detailed financial information, business operations, and management analysis, which fits the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-14 Korean
[기재정정]주요사항보고서(회사합병결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding the cancellation/withdrawal of a previously announced merger between Kangstem Biotech and Primoris Therapeutics. It details the board's decision to terminate the merger agreement due to economic uncertainty and market volatility. Since this document is a formal regulatory filing announcing a significant corporate event (M&A cancellation) and does not fit into the specific 'M&A Activity' category (which typically covers proposals or active bids) or other categories, it is classified as a Regulatory Filing (RNS) as per the fallback rule.
2025-05-09 Korean
철회신고서
M&A Activity Classification · 95% confidence The document is a '철회신고서' (Withdrawal Statement) filed by Kangstem Biotech regarding the cancellation of a previously announced merger with Primo리스테라퓨틱스. Since the document pertains to the cancellation of a merger/takeover bid, it falls under M&A activity. Given the specific nature of the filing as a formal regulatory withdrawal of a merger, it is classified as M&A Activity (TAR).
2025-05-09 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (퓨어스템-에이디주(FURESTEM-AD Inj.)의 반복투여 제1/2a 임상시험계획 변경승인신청)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from a Korean company (Kangstem Biotech) submitted to the Korea Exchange (KRX). It details a 'Major Management Matter' regarding an application for a change in a clinical trial plan (IND amendment). This type of disclosure is a standard regulatory announcement for publicly traded companies in Korea to inform investors of material developments in their R&D pipeline. Since it does not fit into specific categories like earnings releases, dividends, or board changes, it falls under the general regulatory filing category.
2025-05-02 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is an official announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, location, purpose, and agenda for the presentation. Since this is an announcement of an event rather than the presentation slides themselves, and it fits the regulatory requirement for disclosing corporate events, it is classified as a Regulatory Filing (RNS).
2025-04-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.